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ABSTRACT
Background: 
Gastric signet ring cell carcinoma (SRCC) appears to have clinical features and survival 
rates particularly different from other histological types. The aim of this study was to 
investigate clinicopathological features and survival outcomes of SRCC and to compare 
them with non-signet ring cell carcinoma (NSRCC).
Methods:
We retrospectively studied 145 patients with non-metastatic gastric carcinoma who 
underwent gastrectomy in our institute from 2005 to 2015. Among them, 36 patients 
(9.4%) with SRCC were compared to 109 patients (90.6%) with NSRCC. 
Results: 
Patients with SRCC presented at a younger age (p=0.001) with more advanced stage 
III-IV disease (p=0.005) and advanced N stages with a higher rate of pN3 (p=0.0001), 
a higher number of invaded lymph nodes (p=0.002) and a higher rate of patients with 
a lymph node ratio exceeding 25% (63.9% vs 36.7, p=0.004). After a median follow 
up of 35.30 months, there was no significant difference in the 5 years overall (OS) 
survival between SRCC and NSRCC ((36.7% vs 45.7%, p=0.206).However, the 5 years 
progressive free survival (PFS) was significantly decreased in case of SRCC (38.7% 
vs 50.9%, p=0.038) with a higher rate of metastasis in (52.9% vs 29.5%, p=0.013) and 
peritoneal recurrence (35.3% vs 9.5%, p<0.0001). The main prognostic factors of PFS 
and OS in SRCC were tumoral stenosis, hypoprotidemia, tumor size, depth of invasion 
(p=0.001), perineural and lymphovascular invasion, the UICC stage and complete 
surgical resection.
Conclusion:
Gastric SRCC have a particular clinicopathological behavior compared to NSRCC 
suggesting its more aggressive character.
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Background
Gastric signet ring cell carcinoma (SRCC) is defined as an 
adenocarcinoma composed of isolated or small groups 
of malignant cells with abundant intracytoplasmic 
mucinas predominant component (more than 50% of 
the tumor).[1, 2]According to Lauren’s classification, 
SRCC and gastric linitis, are part of the diffuse type.
[3]Another Japanese classification separates gastric 
adenocarcinoma into two groups: differentiated and 
undifferentiated.[4]”Differentiated” cancers include 
well-differentiated, moderately differentiated and 
papillary adenocarcinoma. “Undifferentiated” cancers 
consist of poorly differentiated adenocarcinoma and 
SRCC.[5] SRCC appears to have clinical features 
and survival rates particularly different from other 
histological types according to the stage at diagnosis. The 
aim of this study was to investigate clinicopathological 
features and survival outcomes of SRCC and to compare 
them with non-signet ring cell carcinoma (NSRCC).
Methods
The medical records of 145 patients who underwent 
curative or palliative gastrectomy for non-metastatic 
gastric adenocarcinoma from January 2005 to 
December 2015 were retrospectively reviewed. From 
all, 36 patients had histologically proven gastric SRCC. 
Exclusion criteria were as follows: metastatic disease, 
other synchronous tumoral location, unknown surgery 
status, unknown vital status; incomplete pathological 
data, and less than 50% of signet ring cells. Demographic 
data (Sex, age), clinical presentation, tumor size, tumor 
location, histopathological variables, (lymph node ratio 
(LNR), microscopic invasions (venous, perineural or 
lymphovascular invasion), TNM stage, type of surgery 
and associated resection were recorded. Lymph node 
metastasis (N stage) and depth of tumor invasion (T 
stage) were classified according to the 8th edition of 
the American Joint Committee on Cancer/International 
Union Against Cancer (AJCC/UICC) TNM staging 
system. 
Statistical analysis 
Continuous data were summarized using descriptive 
statistics (mean, standard deviation (SD), median, 
minimum, and maximum values). Categorical data 
were summarized using frequency and percentages. 
Clinicopathological differences between NSRCC 
and SRCC were compared with the Chi-square test 
for categorical variables. Overall survival (OS) was 
calculated as the time from surgery to death of any cause 
or the last follow-up date.  Progressive-free survival 
(PFS) was measured from the time of surgery to initial 
tumor relapse (local or distant recurrence) or the initial 
tumor progression in patients with incomplete resection. 
Survival curves were generated using the Kaplan-Meier 
(KM) method and then compared with the log-rank test. 
Differences were considered to be statistically significant 
when p < 0.05. All statistical analyses were performed 
using SPSS version 20.0.
Results
Of 145 patients, there were 93 males and 52 females 
(1.78:1) with a mean age of 61.48 ± 12.86 years. 36 
patients (9.4%) had signet ring cell carcinoma and 109 
patients (90.6%) had non-signet ring cell carcinoma. 
Clinical and therapeutic features of patients with SRCC 
are summarized in Table 1.  
Table 1: Clinical, and therapeutic features of patients with 
gastric signet ring cell carcinoma.
Variables No of 
patients
%
Age (mean, 
range, 
years) 
54.25 (29-85)
≥60 years 9 25%
<60 years 27 75%
Gender Men 21 58.3%
Women 15 41.7%
Symptoms Gastric pain 34 94.9%
Vomiting 15 41.7%
Melena 1 2.8%
Hematemesis 3 8.3%
Abdominal mass 1 2.8%
Asthenia 28 77.8%
Anorexia 29 80.6%
Weight Loss 31 86.1%
Dysphagia 31 2.8%
Tumor 
location
Cardia 3 8.3%
Gastric fundus 12 33.3%
Gastric antrum 19 52.8%
Whole stomach 2 5.6%
Stenosis No 27 75%
Yes 9 25%
Surgical 
resection
TG 23 63.9%
PG 13 36.1%
MVR No 28 77.8%
Yes 8 22.2%
LND D1 4 11.1%
D1.5 8 22.2%
D2 24 66.7%
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Treatment Surgery alone 10 27.8%
NACT+S+CT/RT 4 11.1%
S+ADJ CT 8 22.2%
S+ADJ RTCT/RT 14 38.9%
TG: total gastrectomy, PG: partial gastrectomy, MVR: multi-
visceral resection, LND: Lymph node dissection; S: surgery, 
NACT: neoadjuvant chemotherapy, ADJ: adjuvant che-
motherapy, ADJ RTCT/RT: adjuvant radio-chemotherapy 
or radiation therapy
  
The mean age of patients with SRCC was 54.25 ± 11.49 
years. The most common complaint was abdominal pain 
(34 patients, 94.9%). The tumor was located in the cardia 
in three cases (8.3%), in the gastric fundus in twelve cases 
(33.3%), in the gastric antrum in 19 cases (52.8%) and in 
the whole stomach in 2 cases (30.4%). Total gastrectomy 
(TG) was the most common surgical procedure, 
performed in 63.9% of cases (23 patients) while36.1% 
of patients had partial gastrectomy (PG). Multivisceral 
organ resection was necessary in eight patients (22.2%). 
We performed a D2 lymph node dissection (LND) in 
24 cases (66.7%), a D1.5 LND in eight patients (22.2%) 
and four patients (11.1%) underwent a D1 lymph node 
dissection (LND). 
Neoadjuvant chemotherapy was administrated in four 
cases (11.1%). Thirty two patients (88.9%) underwent 
primary surgical resection which was followed by 
adjuvant chemotherapy in eight cases (22.2%), adjuvant 
radiation therapy or concomitant radio chemotherapy in 
14 cases (38.9%) and ten patients (27.8%) were treated by 
exclusive surgical resection (Table 1).
 The pathological features of patients with SRCC are 
listed in table 1. Complete surgical resection R0 was 
achieved in 32 patients (88.9%) and four patients (11.1%) 
had incomplete resection (R1/R2). The mean tumor 
size was 74.3 ± 46.53 mm and 61.1% of lesions exceeded 
50mm. Perineural and lymphovascular invasion were 
found in 21 patients (58.3%). Depth of tumor invasion 
according to the 8th edition AJCC/ UICC TNM system 
was pT1 in 2 cases (5.6%), pT2 in 5 cases (13.9%), pT3 in 
17 cases (47.2%) and pT4in 12 cases (33.3%).
The mean number of retrieved lymph node was 22.28 
± 9.48 (range, 9 - 50) with less than 15 extracted LN 
in seven cases (19.4%). Lymph node metastasis was 
found in 32 patients (88.9%) and the mean number of 
metastatic lymph node was 11.81 ± 8.61 (range, 1-38). 
LNR was greater than 25% in 66.7% of cases. Thirty 
patients were staged pN2-N3 (83.3%) and six patients 
(16.7%) were staged pN0-N1. Advanced stages (stage III 
and IV) were found in 78.8% of cases according to the 
AJCC classification.
Clinicopathologic characteristics were compared 
between signet ring cell carcinoma (SRC) and non-signet 
ring cell carcinoma (NSRC) and represented in Table 2.
Table 2:  Pathological characteristics of patients with SRCC
Variables No of 
patients
%
Tumor 
size (mean, 
range, mm) 
34 mm 
(range, 
15mm-
60mm)
<50mm 14 38.9%
≥50mm 22 61.1%
pT stage pT1 2 5.6%
pT2 5 13.9%
pT3 17 47.2%
pT4 12 33.3%
pN stage pN0 4 11.1%
pN1 2 5.6%
pN2 7 19.4%
pN3a 14 38.9%
pN3b 9 25%
pM stage pM0 32 88.9%
pM1 4 11.1%
AJCC stage I 2 5.6%
II 6 16.7%
III 25 66.7%
IV 4 11.1%
NRLN 
(mean, 
range)
22 (min 
9-max 50)
NRLN <15 LN 7 19.4%
NRLN ≥15 LN 29 80.6%
NMLN 
(mean, 
range)
11.81 (min 
1-max38)
LNR0 4 11.1%
LNR1 2 5.6%
LNR2 6 16.7%
LNR3 26 66.7%
PNI No 15 41.7%
Yes 21 58.3%
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LVSI No 15 41.7%
Yes 21 58.3%
Resection R0 32 88.9%
R1/R2 4 11.1%
NRLN: number of retrieved lymph node, NMLN: number 
of metastatic lymph node, LNR: lymph node ratio, LNR0: 
LNR=0; LNR:0%< LNR≤10%; LNR2: 10%<LNR≤25%, 
LNR3: LNR>25%, PNI: Perineural evasion; LVSI: lympho-
vascular space invasion.
Signet ring cell carcinoma presented at a younger age 
(p= 0.001) with no significant difference in gender.
Most of cases of SRCC were located in the middle and 
lower third of the stomach (33.3% and 52.8% respectively). 
Patients with signet ring cell carcinoma were more likely 
to present with more advanced stage III-IV disease 
(77.8% vs 51.4%, p = 0.005).A depth of tumor invasion 
greater than T2 was found more frequently in patients 
with SRCC (80.6%) than in those with NSRCC (69.7%). 
Advanced N stages were significantly more prevalent 
in SRCCs with particularly a higher rate of pN3 (63.9% 
vs 22%, p 0.0001), a higher number of invaded lymph 
nodes (11.81 vs 6.82, p = 0.002), and a higher rate of 
patients with a lymph node ratio exceeding 25% (63.9% 
vs 36.7, p = 0.004).
The median follow up was 35.30 months (range 2-139 
months). After exclusion of five cases of postoperative 
death and one patient lost of view, there was no significant 
difference in the 5 years overall survival between SRCC 
and NSRCC (36.7% vs 45.7%, respectively, p=0.206). 
However, patients with SRCC stage pT4 seems to have 
a worse 5 years OS compared to those with NSRCC 
without statistically significant difference (0 vs 23.6% 
respectively, p=0.068). 
The univariate analysis of the prognostic factors 
associated of the 5 years OS of SRCC showed that the 
tumoral stenosis (p=0.039), hypoprotidemia (<0.0001), 
the depth of invasion (p=0.003), perineural invasion 
(PNI) (<0.0001), lymphovascular space invasion (LVSI) 
(<0.0001), and UICC stage (p=0.007) (Figure 1) were the 
main prognostic factors of overall survival in SRCC 
(Table 3).
The overall survival was not correlated to the type of 
Figure 1: Kaplan-Meier (KM) survival curves of OS accor-
ding to the AJCC stage. There were significant differences 
(p=0.007).
Variables SRCC NSRCC p
Gender Male 21 (58.3%) 72 (66.1%) 0.402
Female 15 (41.7%) 37 (33.9%)
Tumor location Upper third 3 (8.3%) 18 (16.5%) 0.06
Middle third 12 (33.3%) 33 (30.3%)
Lower third 19 (52.8%) 58 (53.2%)
Whole 2 (5.6%) 0
Age ≤ 65 years 31 (86.1%) 59 (54.1%) 0.001
> 65 years 5 (13.9%) 50 (45.9%)
Tumor size <50 mm 14 (38.9%) 44 (40.4%) 0.875
≥50 mm 22 (61.1%) 65 (59.6%)
pT stage pT1-T2 7 (19.4%) 33 (30.3%) 0.207
pT3-T4 29 (80.6%) 76 (69.7%)
Table 3: Comparison of the Clinicopathological Characteristics and survival outcomes of Patients with Signet-Ring Cell Carcino-
ma (SRC) and non-signet ring cell carcinoma (NSRC)
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gastrectomy and the lymphadenectomy extend.
The 5 years overall survival was higher when complete 
surgical resection (R0) is achieved, compared to R1/R2 
resection (41% vs 0% respectively, p=0.069). The number 
of retrieved lymph node exceeding 15 seems to enhance 
the 5 years OS (38.7% in case of more than 15 retrieved 
LN and 21.4% if the NRLN was less than 15 LN, p=0.330). 
According to N stage, patients with pN0-N1 stages had 
better 5 years OS rate compared to patients with pN2-N3 
(62.5% vs 30%, p=0.431).
The 5 years progressive free survival (PFS) was 
significantly decreased in SRCC compared to NSRCC 
(38.7% vs 50.9% respectively, p=0.038) (Figure 2). 
From the 145 patients, 49 patients (33.8%) presented a 
metastatic recurrence with significant higher rate of 
metastasis in SRCC compared to NCRCC (52.9% vs 
29.5% respectively, p=0.013). Moreover, we found that 
the rate of peritoneal recurrence was significantly higher 
in patients with SRCC compared to those with NSRCC 
(35.3% vs 9.5% respectively, p<0.0001). Figure 2: Kaplan-Meier survival curves of PFS by Histologi-cal type. There were significant differences betwen SRC and 
NSRC (p=0.038).
The 5 years PFS rate of SRCC was 38.7% and the 10 years 
PFS rate was 23.2%.Univariate analysis showed that 
pN stage pN0 4 (11.1%) 22 (20.2%) <0.0001
pN1 2 (5.6%) 29 (26.6%)
pN2 7 (19.4%) 34 (31.2%)
pN3 23 (63.9%) 24 (22%)
LNR ≤ 25% 13 (36.1%) 69 (63.3%) 0.004
>25% 23(63.9%) 40(36.7%)
NMLN 11.81 ±8.611 6.82±7.297 0.002
UICC stage Stage I-II 8 (22.2%) 53 (48.6%) 0.005
Stage III-IV 28 (77.8%) 56 (51.4%)
LVSI No 15 (41.7%) 58 (53.2%) 0.230
Yes 21 (58.3%) 51 (46.8%)
PNI No 15 (41.7%) 61 (56%) 0.136
Yes 21 (58.3%) 48 (44%)
Metastatic recurrence No 16 (47.1%) 74 (70.5%) 0.013
Yes 18 (52.9%) 31 (29.5%)
Peritoneal recurrence No 24 (64.7%) 95 (90.5%) <0.0001
Yes 12 (35.3%) 10 (9.5%)
5 years OS 36.7% 45.7% 0.206
5 years PFS 38.7% 50.9% 0.038
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tumoral stenosis (p=0.042), hypoprotidemia (<0.0001), 
tumor size (p=0.049), depth of invasion (p=0.001), PNI 
(<0.0001), LVSI (<0.0001), UICC stage (p=0.026) (Figure 
3) and complete surgical resection (p=0.021) were the 
main prognostic factors of PFS in SRCC (Table 3).
Figure 3: Kaplan-Meier (KM) survival curves of PFS 
according to AJCC stage. There were significant differences 
between stage I-II and stage III-IV (p=0.026).
The PFS was not correlated to the type of gastrectomy 
and the lymphadenectomy extend. However, the 5 years 
PFS of patients with more than 15 retrieved lymph nodes 
seems to be improved compared to those with less than 
15 retrieved lymph nodes (41.4% vs 25.7% respectively, 
p=0.588). According to N stage, patients with pN0-N1 
stages had a better 5 years PFS rate compared to patients 
with pN2-N3 (50% vs 37%, p=0.514). 
Discussion
Our study suggests that SRCC are frequently 
characterized by larger tumor size with stenosis, 
advanced stage, and presence of LNI, PNI and lymph 
node metastasis as well as a different pattern of spread 
and recurrence. The study of predictive factors of 
survival and recurrence suggest that the prognosis of 
SRCC depends not only on the classic prognostic factors 
recognized in all gastric adenocarcinoma, but also on the 
stenotic nature of the lesions and the nutritional status of 
patients. The type of gastrectomy does not affect long-
term results if resection margin is adequate.
SRCC have clinical features that distinguish them from 
other histological types and the prognosis of these 
cancers remains controversial because of their specific 
behavior that may suggest an adjustment of therapeutic 
modalities.
Many studies reported that gastric SRCC is commonly 
more frequent in young patients and females[6, 7] and 
seems to be related to hormonal status.[8] Similar results 
were found in our study with a significantly higher rate 
of patients under 65 years of age in SRCC compared 
to NSRCC (86.5% vs 54.1%; p=0.001). However, we 
observed that the male to female ratio was similar for 
the two groups which is line with the results of Li and 
al who compared 4097 cases of NSRCC to 662 cases of 
SRCC without significant difference in gender (the rate 
of male was 67.3% vs 68% respectively and the rate of 
female was 32.7% vs 31.1% respectively, p=0.418).[9]
Nie et al reported in their recent meta-analysis of 19 
studies including 35947 cases, that SRCC tends to be 
located in the middle and lower third of the stomach 
(OR=0.62, 95% CI=0.47-0.81, P<0.001; I² =82.0%, P<0.001) 
compared to non-signet ring cell carcinoma (NSRCC).
[10] We also reported that most of cases of SRCC were 
located in the lower third (52.8%) and the middle third 
(33.3%) of the stomach. We found that patients with 
SRCC were more likely to present at later stages, with a 
greater proportion of patients presenting at AJCC stage 
III (66.7%), with deeper parietal invasion and a higher 
rate of lymph node metastasis which is in line with the 
results of Taghavi and Piessen.[7, 11]
Lymphovascular and perineural invasion are more 
commonly seen in gastric SRCC. In fact, Kwon et al. 
reported that the rate of PNI and LVSI were respectively 
7.8% and 11.8% in early SRCC and 56.1% and 64.9% in 
advanced SRCC.[12] In our study, 58.3% of patients had 
PNI and LVSI compared to 44% and 46.8% respectively 
in NSRCC.  We also found that patients with SRCC 
were more likely to present with larger tumor size, 
since 61.1% of tumors measured more than 50mm. Chen 
and al reported that according to Lauren classification, 
diffuse and mixed tumors were significantly associated 
with larger tumors exceeding 80mm.[13]
Although most authors agree on the poor prognosis of 
diffuse type of gastric carcinoma according to the Lauren 
classification, the prognosis of SRCCs as a particular 
entity remains debated and varies according to stage 
at diagnosis. Indeed, in early gastric cancer, some 
studies showed that early SRCC has a better prognosis 
than NSRCC.[12, 14, 15]Other authors demonstrated 
no difference in survival between the two histological 
groups in the early stages.[16, 17] However, in advanced 
gastric cancer, Li et al[9]and Piessen et al.[11]found 
that the 5-years survival rate of SRCC was significantly 
poorer than that of NSRCC. 
In our study the 5-year overall survival rate was 35.7%. 
Regarding tumor stage, the 5 years overall survival was 
shorter in stage III and IV compared to stage I and II 
(22.8% vs 72.9%, p=0.007). Similar rates were reported 
by Liu et al with a 5 years OS of 93.9% in stage I, 58.7% 
in stage II and 25.3% in stage III and IV.[18] Few studies 
investigated the recurrence and progressive free survival 
in SRCC according the common prognostic factors. In 
our study, the rate of recurrence was 55.6% and the 5 
years progression-free survival rate was 38.7%. Lower 
rates of relapses were reported by Voron et al (45.75%) 
and Zhang et al (45%).[19, 20] Moreover, in our study 
we reported a higher rate of distant metastasis in SRCC 
compared to NSRCC (52.9% vs 29.5%, p=0.013) which 
is in line with the results of Postlewait and al who 
compared the outcomes of 312 patients with SRCC to 
456 patients with NSRCC and suggested a significant 
difference in term of distant relapses (28.2 % vs 20.2%, 
respectively, p=0.013).[21] Piessen and al[11] analyzed 
the trend of recurrence after a complete resection 
between 23 cases of  SRCC and 42 cases of NSRCC and 
found that peritoneal relapses occurred more frequently 
in patients with SRCC (52.2% vs 21.4%, p=0.001) which 
is similar to our finding. 
Lymph node metastasis and depth of parietal invasion 
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are the most important prognostic factors of gastric 
carcinoma.[22-25] In the majority of studies analyzing 
the survival outcomes of SRCC, the depth of invasion, as 
well as LN metastasis, are the independent prognostic 
factors of recurrence and survival.[18-20] In our study, 
pT stage was also significantly correlated to survival 
outcomes and the 5-years OS rate and PFS rate were 
lower in patients with pN2-N3 compared to those with 
pN0-N1 (30% and 37% respectively vs 62.5% and 50%). 
However, the difference was not significant, and this 
could be explained by the particularly high rate of lymph 
node involvement in our series (only 4 patients were 
staged pN0) but also the reduced number of patients.
Although the prognostic value of tumor size remains 
debatable, it has been reported to be an independent 
prognostic factor by many authors.[26, 27]In our study, a 
tumor size more than 50 mm was significantly associated 
with a decline in overall survival as well as progression-
free survival which is consistent with the results of Liu 
et al who reported a decrease of the 5-years OS in tumors 
larger than 50mm (16.7% vs 48.8% p<0.001).[18]
Several studies investigated the pejorative prognostic 
value of lymphovascular space invasion and perineural 
invasion in gastric cancer.[28-32] Moreover, this 
pejorative prognostic effect of PNI and LVI was also 
found in SRCC. In fact, in the study by Liu et al[18], the 
5-years OS was significantly decreased in the presence 
of LVI (49.4% versus 15.1%, p<0.001) and PNI (46.3% 
versus 21.4%, p<0.001) which is in line with our finding.
In a study comparing 218 patients with SRCC to 
1221 patients with NSRCC, Zhang et al reported that 
curative resection with negative margins represents an 
independent predictor of overall survival in the subgroup 
of patients with SRCC (HR=2.878, 95% CI=1.865–4.440, 
p<0.001).[20] In our study, both of OS and PFS were 
significantly improved by complete surgical resection. 
However, the extend of gastrectomy was not correlated 
to survival outcomes, in case of complete resection, and 
total gastrectomy resulted in a worse 5 years OS and PFS. 
These findings are supported by many other authors. In 
the retrospective study of Voron et al, including a total 
of 899 SRCC treated by total gastrectomy in 576 cases 
(60.7%) and partial gastrectomy in 353 cases (39.3%), 
complete surgical resection was achieved in 79.8% of 
cases and the overall survival was not correlated to the 
type of gastrectomy on multivariate analysis ( HR=0.900, 
95% CI= 0.718-1.128, p<0.359).[19] Despite a higher risk 
of lymph node involvement in SRCC, there is no specific 
recommendation about the extent of lymphadenectomy 
for advanced SRCC. As for other histological types, a 
modified D2 lymphadenectomy retrieving at least 15 
lymph nodes is recommended.[33] Thus, we found a 
gain in terms of OS and PFS if the number of removed 
lymph nodes was greater than 15 LN, even if the 
difference was not statistically significant (38.7% and 
41.7% respectively if the NRLN was greater than 15 LN, 
21.4% and 25.7% respectively if the NRLN was less than 
15 LN).
 Several studies showed that malnutrition, especially 
hypoprotidemia and weight loss, were a prognostic 
factor for survival and recurrence.[34, 35] However, 
in studies dedicated to gastric SRCC, the long-term 
prognostic value of hypoprotidemia has rarely been 
evaluated. Voron et al reported that cancer related 
malnutrition was significantly associated to a worse OS 
in SRCC as well as NSRCC.[19]  However, in the present 
report, the 5 years OS was significantly reduced with 
hypoprotidemia (52.5% vs 0%, p<0.0001) and it was the 
same for the 5 years PFS (55.5% vs 0%, p=0.001). Weight 
loss of more than 10% of the usual weight was also 
associated to lower rate of 5 years OS (23.7% vs 45.5% 
if the weight loss was less than 10%) and a lower rate 
of 5 years PFS (30.3% vs 54.5% if the weight loss was 
less than 10%). We also found that patients presenting 
with tumoral stenosis had a worse OS and PFS which is 
consistent with the report of Chen et al.[13]
Despite the limited number of patients enrolled in this 
retrospective and single institution study, we suggest 
that SRCC remain an aggressive clinical subtype of 
gastric cancer characterized with advanced stage and a 
worse survival outcome compared to NSRCC. 
Conclusion
The incidence of SRCC is increasing in recent years 
and their prognosis seems to be equivalent to that of 
gastric adenocarcinoma or better in the early stages. 
However, it would be more reserved in the advanced 
stages. Although this study helped to describe clinical 
and histological features and survival outcomes, it has 
some limitations due to small sample size. Clinical 
studies with larger patient groups and comparative 
study with NSRCC could be helpful to understand its 
clinicopathological behavior.
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